The safety of celecoxib in cutaneous hypersensitivity reactions with nonsteroidal anti-inflammatory drugs: a single-center care experience
Alergologia Polska - Polish Journal of Allergology · 2022 · 9 (4) · 250-255
DOI: 10.5114/pja.2022.122005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alergologia Polska - Polish Journal of Allergology, 2022. Verfasst von Mehmet Cakmak. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
Introduction
Aspirin/non-steroidal anti-inflammatory drugs (NSAIDs) are frequently prescribed, and hypersensitivity reactions to these drugs are frequently observed in clinical practice.
Aim
To evaluate the safety of celecoxib in patients with a history of cutaneous hypersensitivity reactions to NSAIDs.Material and methods: A retrospective evaluation was made of a total of 113 patients with a history of cutaneous hypersensitivity reactions to NSAIDs who underwent a drug challenge test with celecoxib.The diagnosis of NSAID hypersensitivity was based on a positive oral aspirin challenge test result or a recorded and significant clinical hypersensitivity reaction to aspirin and/or other NSAID-induced reaction.
Results
A total of 113 patients (40 (35.4%) male, 73 (64.6%) female) with a mean age of 39.64 ±12.65 years underwent the drug challenge with celecoxib.Atopy was determined in 40 (35.4%)patients.The most common accompanying allergic diseases were asthma in 46 (40.7%) patients and allergic rhinitis in 37 (32.7%)patients.The most common NSAIDs responsible for the allergic reaction were diclofenac (48.7%), flurbiprofen (47.8%), ketoprofen (47.8%), and aspirin (45.1%).No allergic reaction to celecoxib was observed in any of the 113 patients who underwent the drug challenge testing.
Conclusions
Celecoxib is a safe alternative drug in patients with a history of cutaneous hypersensitivity reactions to NSAIDs.
Zitieren
APA
Cakmak, M. (2022). The safety of celecoxib in cutaneous hypersensitivity reactions with nonsteroidal anti-inflammatory drugs: a single-center care experience. Alergologia Polska - Polish Journal of Allergology, 9(4), 250-255. https://doi.org/10.5114/pja.2022.122005
Vancouver
Cakmak M. The safety of celecoxib in cutaneous hypersensitivity reactions with nonsteroidal anti-inflammatory drugs: a single-center care experience. Alergologia Polska - Polish Journal of Allergology. 2022;9(4):250-255. doi:10.5114/pja.2022.122005
BibTeX
@article{Cakmak2022,
author = {Cakmak, Mehmet},
title = {The safety of celecoxib in cutaneous hypersensitivity reactions with nonsteroidal anti-inflammatory drugs: a single-center care experience},
journal = {Alergologia Polska - Polish Journal of Allergology},
year = {2022},
volume = {9},
number = {4},
pages = {250--255},
doi = {10.5114/pja.2022.122005}
}
EUVIMED